Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Alice T. Shaw, MD
|
|
Give Review
Alice Shaw practices Oncology. She graduated from Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care Alice Shaw is a published doctor. She published 52 publications, including: 'Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.' Alice Shaw accepts all Medicare patients.
Publications
- Complex renal cysts associated with crizotinib treatment.
- Lipodermatosclerosis secondary to pemetrexed use.
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
- Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung Cancer treated with radiotherapy for br...
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
- Developing biomarker-specific end points in lung Cancer clinical trials.
- Alectinib Salvages CNS Metastases in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib.
- Patient-derived models of acquired resistance can identify effective drug combinations for Cancer.
- Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib.
- Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic Lung adenocarcinomas.
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib.
- Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
- Genotyping Lung Cancer Is an Investment in the Future.
- ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond.
- Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
- Ceritinib in ALK-rearranged non-small-cell lung Cancer.
- The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung Cancer.
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer.
- Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung Cancer.
- Tyrosine kinase gene rearrangements in epithelial malignancies.
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer.
- Acquired resistance to crizotinib from a mutation in CD74-ROS1.
- Crizotinib versus chemotherapy in advanced ALK-positive lung Cancer.
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
- Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
- ALK in Lung Cancer: Past, Present, and Future.
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung Cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung Cancer.
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer.
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.
- Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer Prognostic, Predictive, or Both?
- Crizotinib and Testing for ALK.
- Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the Lung.
- Selective killing of K-ras mutant Cancer cells by small molecule inducers of oxidative stress.
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung Cancers harboring the fusion oncogene EML4-ALK.
- Targeting anaplastic lymphoma kinase in lung Cancer.
- Genotypic and histological evolution of lung Cancers acquiring resistance to EGFR inhibitors.
- New Targets in Advanced NSCLC: EML4-ALK.
- One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung Cancer.
- Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell Lung ca...
- Anaplastic lymphoma kinase inhibition in non-small-cell lung Cancer.
- Clinical features and outcome of patients with non-small-cell lung Cancer who harbor EML4-ALK.
- Sprouty-2 regulates oncogenic K-ras in Lung development and tumorigenesis.
- Future of early detection of lung Cancer: the role of mouse models.
- Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions.
- Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung Cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung Cancer: a single-group, multicentre, phase 2 trial.
- Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Stand...
Schools
Harvard Medical School
Mass General Hospital
DfciPartners
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. John Koreth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myles A. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerry L. Massman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian M. Wolpin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Katherina Z. Calvillo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Toni K. Choueiri, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|